CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and HK$23.22, translating to a volume-weighted average cost of HK$22.9989 per share and a total cash outlay of HK$0.22 million.

The transaction reduced the number of issued shares (excluding treasury stock) to 301.72 million, down 0.0031% from the level reported on 28 February 2026. Treasury shares rose to 506,000, while the overall issued share count remained unchanged at 302.22 million because the repurchased shares have been retained in treasury rather than cancelled.

The buyback forms part of the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, the company has repurchased 506,000 shares under this authority, equivalent to 0.17% of the issued shares outstanding on the mandate date.

Under Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 30 April 2026.